Steven Prestrelski - Net Worth and Insider Trading
Steven Prestrelski Net Worth
The estimated net worth of Steven Prestrelski is at least $2 Million dollars as of 2024-12-27. Steven Prestrelski is the Chief Scientific Officer of Xeris Biopharma Holdings Inc and owns about 569,780 shares of Xeris Biopharma Holdings Inc (XERS) stock worth over $2 Million. Details can be seen in Steven Prestrelski's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Steven Prestrelski has not made any transactions after 2022-02-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Steven Prestrelski
Steven Prestrelski Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Steven Prestrelski owns 1 companies in total, including Xeris Biopharma Holdings Inc (XERS) .
Click here to see the complete history of Steven Prestrelski’s form 4 insider trades.
Insider Ownership Summary of Steven Prestrelski
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| XERS | Xeris Biopharma Holdings Inc | 2022-02-22 | Chief Scientific Officer |
Steven Prestrelski Latest Holdings Summary
Steven Prestrelski currently owns a total of 1 stock. Steven Prestrelski owns 569,780 shares of Xeris Biopharma Holdings Inc (XERS) as of February 22, 2022, with a value of $2 Million.
Latest Holdings of Steven Prestrelski
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| XERS | Xeris Biopharma Holdings Inc | 2022-02-22 | 569,780 | 3.50 | 1,994,230 |
Holding Weightings of Steven Prestrelski
Steven Prestrelski Form 4 Trading Tracker
According to the SEC Form 4 filings, Steven Prestrelski has made a total of 5 transactions in Xeris Biopharma Holdings Inc (XERS) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Xeris Biopharma Holdings Inc is the sale of 11,228 shares on February 22, 2022, which brought Steven Prestrelski around $27,172.
Insider Trading History of Steven Prestrelski
- 1
Steven Prestrelski Trading Performance
Steven Prestrelski Ownership Network
Steven Prestrelski Owned Company Details
What does Xeris Biopharma Holdings Inc do?
Who are the key executives at Xeris Biopharma Holdings Inc?
Steven Prestrelski is the Chief Scientific Officer of Xeris Biopharma Holdings Inc. Other key executives at Xeris Biopharma Holdings Inc include Chief Financial Officer Steven Pieper , See Remarks Shannon John Patrick Jr , and director & See Remarks Paul R Edick .
Xeris Biopharma Holdings Inc (XERS) Insider Trades Summary
Over the past 18 months, Steven Prestrelski made no insider transaction in Xeris Biopharma Holdings Inc (XERS). Other recent insider transactions involving Xeris Biopharma Holdings Inc (XERS) include a net purchase of 25,200 shares made by John P. Schmid , a net purchase of 30,769 shares made by Shannon John Patrick Jr , and a net purchase of 28,000 shares made by Steven Pieper .
In summary, during the past 3 months, insiders sold 0 shares of Xeris Biopharma Holdings Inc (XERS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Xeris Biopharma Holdings Inc (XERS) were sold and 104,779 shares were bought by its insiders, resulting in a net purchase of 104,779 shares.
Xeris Biopharma Holdings Inc (XERS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Xeris Biopharma Holdings Inc Insider Transactions
Steven Prestrelski Mailing Address
Above is the net worth, insider trading, and ownership report for Steven Prestrelski. You might contact Steven Prestrelski via mailing address: C/o Xeris Pharmaceuticals, 180 N. Lasalle Street, Suite 1800, Chicago Il 60601.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
